News

  • 15 December 2010

    Creabilis SA, a clinical stage European biotechnology company addressing unmet medical needs in dermatology, today announced positive results in the Phase IIa study of its lead product CT327 in atopic dermatitis.

  • 8 November 2010

    Kuros Biosurgery AG, a biotechnology company focused on the development of novel biomaterials and bioactive-biomaterial combination products for trauma, wound and spinal indications, announced today that it has regained rights to a number of selected wound care and trauma clinical candidates that were previously licensed to Baxter International Inc.

  • 7 October 2010

    Richter announces the Acquisition of PregLem for an initial cash consideration of CHF150 million (€114 million) and further milestone payments of up to CHF295 million (€223 million). The Acquisition values PregLem at up to CHF445 million (€337 million)

  • 28 September 2010

    Creabilis SA, a clinical stage European biotechnology company addressing significant unmet medical needs in dermatological diseases, today announced the appointment of Eliot Forster as its new Chief Executive Officer. Dr Forster brings to Creabilis significant drug development experience having brought a number of molecules to market.

  • 15 September 2010

    Creabilis SA, a clinical stage European biotechnology company addressing significant unmet medical needs in dermatological diseases, today announced the appointment of George F. Horner III as its Chairman. Mr Horner brings to Creabilis an unrivalled track record in building successful biotech businesses that have generated significant value for their shareholders.